Research
Hormonal
GIP receptor agonism and antagonism both lead to weight reduction.
Both GIP receptor agonists and antagonists could be explored for obesity treatment strategies.
StrongSupportsmedium confidence
It details examples of how to reconcile the contradictory findings that both GIP receptor agonism and antagonism cause weight reduction.
Why this rating
The review discusses conflicting data and provides examples from current research.
Source
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity
Robert H. Gaffey et al. · Expert Opinion on Investigational Drugs · 2024
DOI 10.1080/13543784.2024.2377319
reviewCited 6×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →